Apellis Pharmaceuticals, Inc. (APLS)

WALTHAM, Mass., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that The New England Journal of Medicine (NEJM) published positive results from the Phase 3 VALIANT study investigating EMPAVELI® (pegcetacoplan) for C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN), which are severe and rare kidney diseases.

Apellis Pharmaceuticals, Inc. (APLS) Presents at Evercore 8th Annual Healthcare Conference Transcript

Apellis Pharmaceuticals, Inc. (APLS) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

WALTHAM, Mass., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that management will participate in webcast fireside chats at the following investor conferences: Citi's 2025 Global Healthcare Conference Date/Time: Tuesday, December 2, 2025 at 2:30 p.m.

Connor Clark and Lunn Investment Management Ltd. lessened its position in shares of Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) by 10.0% in the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 118,724 shares of the company's stock after selling 13,171 shares during the period.

Apellis Pharmaceuticals, Inc. ( APLS ) Stifel 2025 Healthcare Conference November 12, 2025 2:40 PM EST Company Participants Timothy Sullivan - CFO & Treasurer David Acheson - Executive Vice President of Commercial Conference Call Participants Annabel Samimy - Stifel, Nicolaus & Company, Incorporated, Research Division Presentation Annabel Samimy Stifel, Nicolaus & Company, Incorporated, Research Division Good afternoon, everyone, and welcome to the Apellis session. It's our pleasure to have CFO, Tim Sullivan; and Chief Commercial Officer, David Acheson, with us today.

WALTHAM, Mass., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced data from a post hoc analysis of the GALE extension study following five years of continuous treatment with SYFOVRE® (pegcetacoplan injection), the leading treatment for geographic atrophy (GA) secondary to age-related macular degeneration (AMD).

WALTHAM, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will present at the Stifel 2025 Healthcare Conference on Wednesday, November 12, 2025 at 2:40 p.m. ET.

APLS shares plunge 31% despite topping Q3 earnings and revenue estimates, as gains were driven by a one-time Sobi payment.

Apellis Pharmaceuticals, Inc. ( APLS ) Q3 2025 Earnings Call October 30, 2025 8:30 AM EDT Company Participants Eva Stroynowski Cedric Francois - Co-Founder, President, CEO & Director David Acheson - Executive Vice President of Commercial Caroline Baumal - Chief Medical Officer Timothy Sullivan - CFO & Treasurer Conference Call Participants Jonathan Miller - Evercore ISI Institutional Equities, Research Division Anupam Rama - JPMorgan Chase & Co, Research Division Steven Seedhouse - Cantor Fitzgerald & Co., Research Division Yigal Nochomovitz - Citigroup Inc., Research Division Colleen Hanley - Robert W. Baird & Co. Incorporated, Research Division Ellen Horste Lachlan Hanbury-Brown - William Blair & Company L.L.C.

While the top- and bottom-line numbers for Apellis Pharmaceuticals (APLS) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Apellis Pharmaceuticals, Inc. (APLS) came out with quarterly earnings of $1.67 per share, beating the Zacks Consensus Estimate of $1.03 per share. This compares to a loss of $0.46 per share a year ago.

WALTHAM, Mass., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), today announced its third quarter 2025 financial results and business highlights.

Apellis Pharmaceuticals (APLS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

WALTHAM, Mass., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced new data from the open-label period of the Phase 3 VALIANT study that reinforce the robust and sustained efficacy of EMPAVELI® (pegcetacoplan), a C3 inhibitor, in patients with C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN), rare and debilitating kidney diseases.

Apellis Pharmaceuticals to Host Conference Call on October 30, 2025, to Discuss Third Quarter 2025 F, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will host a conference call and webcast to discuss its third quarter 2025 financial results on Thursday, October 30, 2025, at 8:30 a.